Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
نویسندگان
چکیده
To select maximally-efficacious, minimally-toxic regimens of combination tumorand immune-targeted therapy, preclinical testing in immune-competent models is required. We previously demonstrated 4-1bb(CD137) stimulation augmented the innate immune response mediated by CD137activated natural killers (NK) cells and the subsequent CD8 T cell adaptive immune response when administered after tumor-targeting, ADCC-competent, mAbs targeting CD20, HER2, and EGFR. As four ongoing clinical trials (NCT01471210, NCT01775631, NCT02110082, NCT01307267) investigate this strategy, the CD8 T cell response stimulated by 4-1bb was determined pre-clinically to be further augmented by PD-1/PD-L1 blockade, and a clinical trial is planned (NCT02179918). Taken together, we hypothesized, sequential tumor-targeting with anti-CD20 mAb, Rituximab, followed by dual immune-targeting with anti-CD137 agonism and PD-1/ PD-L1 blockade would be efficacious and tolerable due to non-overlapping immune mechanisms and toxicity profiles. Preclinical modeling was performed in a therapeutic, syngenic, A20 lymphoma BALB/c model combining antiCD20 mAb (IgG2a-18B12, delivered intraperitoneally, i.p. on d5) with agonistic anti-CD137 mAb (IgG2a-2A, i.p. d6) and anti-PD-1 mAb (IgG2a-RMPI-14, i.p. d6) with intratumoral (i.t.) and circulating (c.) immune responses phenotyped by flow cytometry and time of flight mass cytometry (CyTOF). Combination immunotherapy with anti-CD137 and anti-PD1 was superior to either monotherapy without anti-CD20 treatment in a dose-dependent manner (p<.001 tumor-growth, p < .001 survival), though no mice were cured long-term. When administered following anti-CD20 treatment, combination immunotherapy with anti-CD137 and anti-PD1 was superior to either monotherapy in a sequence-dependent manner (p<.001 tumor-growth, and p < .001 survival) with all mice cured long-term and protected from re-challenge when anti-CD20 preceded combination immunotherapy. Target expression was dynamic, as exemplified by highest CD137 expression on i.t.Tregs, followed by i.t.CD8 T cells. Following anti-CD20 mAb treatment, 1) CD137 expression increased 5-10x on i.t. NKs and 2-6x increase on c.NKs; 2) PD-L1 expression increased on A20 tumor and i.t.CD8 T cells, and minimally on i.t.NKs; and 3) PD-1 expression increased on i.t. Tregs, i.t.CD8 T cells, and i.t.NKs. Treatment with antiCD137 agonist and PD-1 blockade 1) increased the ratio of i.t.NKs/Tregs and c.CD8 T cells/Tregs, and 2) increased i.t. and c.CD8 T cell tumor-specific IFN-g secretion and i.t. and c.NK cell degranulation. Laboratory and necropsy studies identified B cell lymphopenia and mild transaminitis which was notably marked with combination immunotherapy. We conclude that sequential tumor-targeting followed by dual immune-targeting is highly-efficacious with predictable toxicity and should be considered for clinical translation to augment three therapies with only marginal activity as monotherapy in advanced, relapsed/ refractory lymphoma. Stanford University, Stanford, CA, USA Full list of author information is available at the end of the article Mueller et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P106 http://www.immunotherapyofcancer.org/content/2/S3/P106
منابع مشابه
Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Immunotherapies targeting the programmed death 1 (PD-1) coinhibitory receptor have shown great promise for a subset of patients with cancer. However, robust and safe combination therapies are still needed to bring the benefit of cancer immunotherapy to broader patient populations. To search for an optimal strategy of combinatorial immunotherapy, we have compared the antitumor activity of the an...
متن کاملOX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Recent studies have highlighted the therapeutic efficacy of immunotherapy, a class of cancer treatments that utilize the patient's own immune system to destroy cancerous cells. Within a tumor the presence of a family of negative regulatory molecules, collectively known as "checkpoint inhibitors," can inhibit T cell function to suppress anti-tumor immunity. Checkpoint inhibitors, such as CTLA-4 ...
متن کاملCombination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
BACKGROUND/AIM The purpose of the present study was to establish an effective immunotherapy by skewing the cosignal balance to be on the positive side by using the combination of monoclonal antibody (mAb) against 4-1BB also known as Cluster of Differentiation (CD) 137 as a co-stimulatory effector and to programmed death-1 (PD-1) to blockade the immune checkpoint. MATERIALS AND METHODS Mice im...
متن کاملCombined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF (V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreated metastatic melanoma and the synergistic effect of dabrafenib, trametinib and anti-PD-1 compare...
متن کاملDual-targeting nanoparticles for reprogrammed T cell responses in the tumor microenvironment
One of the largest obstacles in cancer immunotherapy involves overcoming the immunosuppressive tumor microenvironment [1]. While many therapies are focused primarily on activating antigen-specific CD8+ T cells, the tumor microenvironment often expresses immunosuppressive cytokines and other immunoregulatory proteins such as checkpoint blockade molecules that diminish their effects [2]. Programm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2 شماره
صفحات -
تاریخ انتشار 2014